52 reports of this reaction
2.0% of all BUPRENORPHINE AND NALOXONE reports
#11 most reported adverse reaction
HYPERHIDROSIS is the #11 most commonly reported adverse reaction for BUPRENORPHINE AND NALOXONE, manufactured by Amneal Pharmaceuticals LLC. There are 52 FDA adverse event reports linking BUPRENORPHINE AND NALOXONE to HYPERHIDROSIS. This represents approximately 2.0% of all 2,589 adverse event reports for this drug.
Patients taking BUPRENORPHINE AND NALOXONE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for BUPRENORPHINE AND NALOXONE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for BUPRENORPHINE AND NALOXONE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 52 FDA reports for BUPRENORPHINE AND NALOXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 2.0% of all adverse event reports for BUPRENORPHINE AND NALOXONE, making it a notable side effect.
If you experience hyperhidrosis while taking BUPRENORPHINE AND NALOXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.